Axogen (AXGN) Could Be 9% Below Fair Value As Growth Narrative Builds

Axogen (AXGN) has drawn fresh attention after recent trading, with the stock closing at $48.28 in its latest session. Investors are weighing that move against its year-to-date and one-year total returns.

For context, Axogen’s 1 day share price return of 2.51% comes after a 7 day share price return that fell 6.2%. However, the 30 day and 90 day share price returns of 6.77% and 12.8% respectively sit alongside a year to date share price return of 55.74% and a very large 1 year total shareholder return of 202.13%, suggesting momentum has been building over time despite shorter term swings.

Scan how Axogen’s recent run compares with other stocks showing strong price and fundamentals momentum across our hand picked 19 high quality undiscovered gems list.

After a move like this, some investors will see Axogen as a story that has largely played out, while others will argue the recent strength only reflects a portion of its potential. The valuation numbers are where that debate becomes clearer.

Most Popular Narrative: 9.3% Undervalued

Axogen’s most followed narrative points to a fair value of $53.22, which sits above the latest close at $48.28 and frames the recent share price strength in a specific way.

Broad-based adoption of Axogen's nerve care algorithm across multiple markets (extremities, oral maxillofacial, breast) and exceptional momentum in activating high-potential accounts signal that the addressable market for nerve repair is still substantially underpenetrated, suggesting a long runway for sustained double-digit revenue growth as awareness and adoption rise.

Read the complete narrative. Read the complete narrative.

Want to see what supports that fair value for Axogen? The narrative focuses on accelerating revenue, a shift from losses to profits, and a rich future earnings multiple. The key is how these moving parts combine over time.

Result: Fair Value of $53.22 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Axogen’s reliance on Avance Nerve Graft and the uncertainties around the ongoing FDA Biologics License Application could quickly challenge this underpriced narrative.

Find out about the key risks to this Axogen narrative.

Another View: Axogen looks expensive on sales based metrics

While Axogen screens as about 10.4% below an estimated fair value of $53.86 using our DCF model, its current P/S ratio of 10.3x is much higher than the US Medical Equipment industry average of 2.9x and a fair ratio of 5.2x. That gap points to meaningful valuation risk if sentiment or growth expectations cool.

Our valuation breakdown sets out how this P/S premium compares to peers and what would need to change for that gap to narrow. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With Axogen showing both strong recent returns and valuation questions, it makes sense to stress test the story yourself and act while the detail is fresh. To weigh the upside against the concerns in a single snapshot, start with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Axogen?

If Axogen has sharpened your focus, do not stop here. Broaden your watchlist now so you are not chasing opportunities after they move.

• Target potential mispricing by scanning companies with strong fundamentals using our focused list of 47 high quality undervalued stocks.
• Strengthen your income stream by checking companies with robust payouts in the 11 dividend fortresses.
• Limit downside shocks by focusing on resilient companies through the 82 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com